知搜-全球专利检索

  1. Login
  2. Sign Up

Search Results

12 records (took 0.024 seconds)

    Modified Fc molecules
    2.
    发明授权
    Modified Fc molecules 有权

    公开(公告)号：US10188740B2

    公开(公告)日：2019-01-29

    申请号：US14796502

    申请日：2015-07-10

    Applicant: AMGEN INC.

    Inventor： Colin V. Gegg ,  Kenneth W. Walker ,  Leslie P. Miranda ,  Fei Xiong

    IPC: A61K39/395 ,  A61K47/48 ,  A61K38/02 ,  C07K16/00 ,  C07K17/00 ,  A61K47/60 ,  A61K47/68

    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

    Modified Fc molecules
    3.
    发明授权
    Modified Fc molecules 有权

    公开(公告)号：US11266744B2

    公开(公告)日：2022-03-08

    申请号：US16206899

    申请日：2018-11-30

    Applicant: AMGEN INC.

    Inventor： Colin V. Gegg ,  Kenneth W. Walker ,  Leslie P. Miranda ,  Fei Xiong

    IPC: C07H21/02 ,  C07H21/04 ,  C12P21/06 ,  C12N1/20 ,  C12N15/00 ,  C12N5/00 ,  C07K16/00 ,  A61K47/68 ,  A61K47/60 ,  A61K38/02 ,  C07K17/00

    Abstract: Disclosed is a process for preparing a pharmacologically active compound, in which at least one internal conjugation site of an Fc domain sequence is selected that is amenable to conjugation of an additional functional moiety by a defined conjugation chemistry through the side chain of an amino acid residue at the conjugation site. An appropriate amino acid residue for conjugation may be present in a native Fc domain at the conjugation site or may be added by insertion (i.e., between amino acids in the native Fc domain) or by replacement (i.e., removing amino acids and substituting different amino acids). In the latter case, the number of amino acids added need not correspond to the number of amino acids removed from the previously existing Fc domain. This technology may be used to produce useful compositions of matter and pharmaceutical compositions containing them. A DNA encoding the inventive composition of matter, an expression vector containing the DNA, and a host cell containing the expression vector are also disclosed.

    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof
    4.
    发明授权
    Anti-TL1A/anti-TNF-alpha bispecific antigen binding proteins and uses thereof 有权

    公开(公告)号：US11104745B2

    公开(公告)日：2021-08-31

    申请号：US16062096

    申请日：2016-12-14

    Applicant: AMGEN INC.

    Inventor： Hailing Hsu ,  Gunasekaran Kannan ,  Kenneth W. Walker ,  Michelle Hortter ,  Edward J. Belouski

    IPC: C07K16/46 ,  C07K16/24 ,  A61K39/395 ,  C07K16/28 ,  C12N15/10

    Abstract: The present invention concerns antigen binding proteins that bind TL1A, including bispecific antigen binding proteins (e.g., antibodies) to TL1A and TNF-α. Such bispecific antibodies can be in a tetrameric immunoglobulin format, in which one heavy chain-light chain pair of the antibody is directed to TL1A and the other to TNF-α. The bispecific antigen binding proteins may also be comprised in an IgG-scFv fusion, in which a conventional tetrameric antibody directed to one antigen is fused to a pair of single chain Fv units directed to the other. The bispecific antigen binding protein may also be comprised in an IgG-Fab fusion, in which a Fab molecule that binds to one antigen is fused to each heavy chain of a conventional tetrameric antibody directed to the other antigen. The invention further relates to uses of the anti-TL1A binding proteins and anti-TL1A/anti-TNF-α antigen binding proteins, and pharmaceutical formulations thereof.

    COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS
    6.
    发明申请
    COMPOSITIONS AND METHODS FOR PRODUCING BIOACTIVE FUSION PROTEINS 审中-公开

    公开(公告)号：US20130217625A1

    公开(公告)日：2013-08-22

    申请号：US13861348

    申请日：2013-04-11

    Applicant: Amgen Inc.

    Inventor： Kenneth W. Walker ,  Colin V. Gegg, JR.

    IPC: C07K14/78 ,  C07K14/435

    CPC classification number: C07K14/78 ,  A61K47/60 ,  C07K14/43504 ,  C07K14/43522 ,  C07K14/524 ,  C07K16/18 ,  C07K2319/00 ,  C07K2319/30 ,  C07K2319/31 ,  C07K2319/35

    Abstract: Disclosed is a composition of matter involving a recombinant fusion protein comprising a a pharmacologically active protein partner, and a small pharmacologically inactive protein domain partner of human origin, such as but not limited to, a 10th fibronectin III domain, a SH3 domain, a SH2 domain, a CH2 domain of IgG1, a PDZ domain, a thrombospondin repeat domain, an ubiquitin domain, a leucine-rich repeat domain, a villin headpiece HP35 domain, a villin headpiece HP76 domain, or a fragment or modification of any of these. Also disclosed are nucleic acids (e.g., DNA constructs) encoding the fusion protein, expression vectors and recombinant host cells for expression of the fusion protein, and pharmaceutical compositions containing the recombinant fusion protein and a pharmaceutically acceptable carrier, and method of producing a pharmacologically active recombinant fusion protein.

Patent Agency Ranking